Testosterone Enanthate

Summary

Testosterone Enanthate (CHEMBL1200335) is an approved small-molecule androgen; indicated across 12 conditions including hypogonadism and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 12 conditions
• Clinical trials: 27
• Chemistry: 400.6 Da · C26H40O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200335
Name	Testosterone Enanthate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9416
ChEBI	CHEBI:9464
Molecular formula	C26H40O3
Molecular weight	400.6
InChIKey	VOCBWIIFXDYGNZ-IXKNJLPQSA-N

SMILES: CCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C

IUPAC name: [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] heptanoate

Pharmacological roles (ChEBI): androgen.

Also known as: Androtardyl, Delatestryl, NSC-17591, Primoteston depot, Testosterone enantate, Testosterone enanthate, Testosterone enanthate ciii, Testosteroni enantas, Xyosted, Xyosted (autoinjector), TESTOSTERONE ENANTHATE, Testosterone Enanthate

Patent coverage: 1,410 distinct patent families (5,104 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

12 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypogonadism	4	MONDO:0002146	HP:0000044
neoplasm	4	MONDO:0005070	EFO:0000616
orchitis	4	MONDO:0006882	EFO:1001078
metastatic prostate carcinoma	2	MONDO:0004956	EFO:0000196
HIV wasting syndrome	2	MONDO:0005797	EFO:0007312
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
prostate adenocarcinoma	2	MONDO:0005082	EFO:0000673
prostate carcinoma	2	MONDO:0005159	EFO:0001663
facioscapulohumeral muscular dystrophy	1	MONDO:0001347	Orphanet:269

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 27.

Phase distribution

Phase	Trials
PHASE2	12
PHASE4	4
PHASE3	4
PHASE1	3
PHASE2/PHASE3	2
PHASE1/PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04601233	PHASE4	NOT_YET_RECRUITING	Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis
NCT00493987	PHASE4	COMPLETED	The Role of 5-alpha Reductase in Mediating Testosterone Actions
NCT01417364	PHASE4	WITHDRAWN	The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men
NCT02734238	PHASE4	COMPLETED	Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery
NCT06689085	PHASE3	RECRUITING	52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
NCT00070733	PHASE3	UNKNOWN	The Effect of 5-Alpha Reductase on Testosterone in Men
NCT00161304	PHASE2/PHASE3	COMPLETED	Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency
NCT01275365	PHASE3	COMPLETED	Optimizing Protein Intake in Older Americans With Mobility Limitations
NCT03674320	PHASE2/PHASE3	WITHDRAWN	Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD
NCT04026880	PHASE3	WITHDRAWN	Testosterone Effects on Pelvic Floor Muscles
NCT03522064	PHASE2	RECRUITING	Bipolar Androgen Therapy + Carboplatin in mCRPC
NCT04363164	PHASE2	RECRUITING	Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
NCT04460872	PHASE2	RECRUITING	Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
NCT06594926	PHASE2	RECRUITING	Working Out M0 Bipolar Androgen Therapy
NCT00001079	PHASE2	COMPLETED	A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss
NCT00260143	PHASE2	COMPLETED	Testosterone and Physical Function in HIV+ Men
NCT00399165	PHASE1/PHASE2	COMPLETED	Oral Androgens in Man-4: (Short Title: Oral T-4)
NCT00475501	PHASE2	COMPLETED	5-Alpha Reductase and Anabolic Effects of Testosterone
NCT02090114	PHASE2	COMPLETED	RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
NCT02248701	PHASE2	TERMINATED	Testosterone Plus Finasteride Treatment After Spinal Cord Injury
NCT02286921	PHASE2	COMPLETED	Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
NCT02697188	PHASE2	COMPLETED	Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
NCT03516812	PHASE2	COMPLETED	Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
NCT00878995	PHASE1	COMPLETED	Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
NCT01962454	PHASE1	COMPLETED	A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers
NCT03123913	PHASE1	COMPLETED	Study of Testosterone and rHGH in FSHD
NCT07568574	Not specified	ENROLLING_BY_INVITATION	Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).